SEC Form 4 · accession 0001209191-15-047734
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John T Curnutte
Officer — Executive Vice President
Period of report
May 28, 2015
Accepted (ET)
May 28, 2015 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 28, 2015 | M | 10,000 | $8.50 | A | 10,000 | D | |
| Common StockF2,F1 | May 28, 2015 | S | 9,000 | $40.20 | D | 1,000 | D | |
| Common StockF3,F1 | May 28, 2015 | S | 1,000 | $41.18 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.50 | May 28, 2015 | M | 10,000 | D | Mar 23, 2011 | Mar 23, 2021 | Common Stock | 10,000 | 123,682 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2015.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.93, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3These shares were sold in a single transaction at a price of $41.18.